As the chemerin analog was administered systemically via a vein, this analysis cannot distinguish direct effects of CG34 on tumor cells from indirect regulation via immune cells, cancer-associated fibroblasts, or other cells of the tumor microenvironment. The gene discussed is RARRES2; the disease is cancer.